Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Nature chemical biology - 1 Apr 2011

Deng Xianming, Dzamko Nicolas, Prescott Alan, Davies Paul, Liu Qingsong, Yang Qingkai, Lee Jiing-Dwan, Patricelli Matthew P, Nomanbhoy Tyzoon K, Alessi Dario R, Gray Nathanael S

Abstract excerpt

Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson's disease. We employed a new, parallel, compound-centric approach to identify a potent and selective LRRK2 inhibitor, LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces dephosphorylation of Ser910 and Ser935 and accumulation of LRRK2 within aggregate structures. LRRK2-IN-1 will serve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to HEK293 Cells

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Pyrimidines

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 21378983
DOI: 10.1038/nchembio.538
PMCID: PMC3287420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.PMID 21378983Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

A step forward for LRRK2 inhibitors in Parkinson's disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.